Cart
sales@molnova.com
Paritaprevir (b)
CAS No. 1221573-85-8
Paritaprevir (b)( —— )
Catalog No. M10838 CAS No. 1221573-85-8
Paritaprevir is a Hepatitis C Virus NS3/4A Protease Inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 39 | In Stock |
|
| 10MG | 52 | In Stock |
|
| 25MG | 81 | In Stock |
|
| 50MG | 140 | In Stock |
|
| 100MG | 254 | In Stock |
|
| 200MG | 457 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameParitaprevir (b)
-
NoteResearch use only, not for human use.
-
Brief DescriptionParitaprevir is a Hepatitis C Virus NS3/4A Protease Inhibitor.
-
DescriptionParitaprevir is a Hepatitis C Virus NS3/4A Protease Inhibitor. The mechanism of action of paritaprevir is as a HCV NS3/4A Protease Inhibitor, and Organic Anion Transporting Polypeptide 1B1 Inhibitor, and Organic Anion Transporting Polypeptide 1B3 Inhibitor, and Breast Y Resistance Protein Inhibitor, and UGT1A1 Inhibitor, and P-Glycoprotein Inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHCV
-
RecptorHCV NS3/4A
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1221573-85-8
-
Formula Weight765.89
-
Molecular FormulaC40H43N7O7S
-
Purity>98% (HPLC)
-
SolubilitySoluble in DMSO
-
SMILESCc1ncc(nc1)C(=O)N[C@H]5CCCCCC=C[C@@H]8C[C@]8(NC(=O)[C@@H]6C[C@@H](Oc3nc4ccccc4c2ccccc23)CN6C5=O)C(=O)NS(=O)(=O)C7CC7
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Todt D, et al. J Antimicrob Chemother. 2017 Jan 18.
molnova catalog
related products
-
Paritaprevir
Paritaprevir (ABT-450, Veruprevir) is a potent HCV NS3/4A protease inhibitor with EC50 of 1 and 0.21 nM for HCV GT 1a and 1b, respectively.
-
PSI-6130
A potent, specific inhibitor of HCV RNA synthesis by inhibiting the NS5B RNA polymerase (EC90=4.6 uM in replicon assay).
-
MK-8325 dihydrochlor...
MK-8325 is a potent, selective pan-genotype HCV NS5A inhibitor with IC50 of 15, 1 and 3 pM for GT1a, GT1b and GT2a, respectively.
